Meiwan Chen received her PhD from Sun Yat-Sen University, China and was a visiting scholar from 2009 to 2010 at University of Mississippi. At present, she is an Associate Professor at Institute of Chinese Medical Sciences, University of Macau and specializes in biomaterial and nanomedicine, especially the development of targeted drug delivery systems for cancer therapy. The research ranges from design and synthesis of novel lipidic and polymeric carriers to mechanistic understanding of delivery barriers and to in vivo studies of relevant tumor models. She has published more than 100 peer-reviewed papers in SCI journals.
J. Li Zhengzhou University Zhengzhou (China)
Dr. Jing-an Li is a professor of Zhengzhou University, China, and his research filed include: Drug delivery and biomaterials. So far, he has published more than 40 academic papers on international academic journals as the first author or corresponding author, including ACS Applied Materials & Interface, Applied Surface Science, Biomaterials Science, and Journal of Materials Chemistry B. He has been serving as the editorial board member of repute journals, such as Current Chinese Biotechnology (Section Editor), Recent Patents on Nanotechnology, Biomed Research International (Lead Guest Editor), Genetics and Molecular Research, Current Drug Delivery (Executive Guest Editor). He was also honored with repute awards, such as “China-Korea Young Scientist Award”, “IAAM Scientist Award”, “IAAM Medal”, and “Outstanding Reviewer Award” of repute journals. Detail information please see: Researchgate: https://www.researchgate.net/profile/Jingan_Li2
M.A.G. Raja Northern Border University Rafha (Saudi Arabia)
Dr. Maria Abdul Ghafoor Raja received his Ph.D. in Pharmacy from the Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Currently, she is an Assistant Professor at the Department of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Rafha, Saudi Arabia. Her research interests include Liposomes, Nanoparticles, Gene delivery, Drug delivery, and novel targeting, Cell culture, 3D cell culture, Anticancer Drug Resistance, and Tumor targeted drug delivery. She has published several articles in ISI-indexed Journals with impact factor.
A. Savaser University of Health Sciences Ankara (Turkey)
Dr. Ayhan SAVASER graduated from Hacettepe University Faculty of Pharmacy in 1988, He received his M.Sc. degree in Pharmaceutical Technology with his thesis on ‘The Studies iNH tablets available on the Turkish drug market’’ in Gulhane Mİlitary Medical Academy. He obtained his Ph.D. degree with ‘‘The Development, in vitro evaluation and bioequivalence of sustained release tablet formulations of diclofenac sodium’’ thesis same Academy in 1999. He worked as assistant professor between 2000-2006 and received his Associate Professor title in 2007 and his received Professor title in 2017. He is currently continuing his research work at the Department of Pharmaceutical Technology, University of Health Sciences, Gulhane Campus, Ankara. Dr. SAVASER has served as BA/BE Evaluation Commission member since 2011 and is the writer of 40 scientific articles, 6 book chapters.
F. Shakeel King Saud University Riyadh (Saudi Arabia)
Dr. Faiyaz Shakeel received a Master degree (M. Pharm) and a PhD in Pharmaceutics from Jamia Hamdard (Hamdard University, New Delhi, India). At Jamia Hamdard. In 2011, he was awarded Young Scientist Award from the Association of Pharmacy Professionals (APP). In March 2016, he has been promoted to Associate Professor at King Saud University. At King Saud University, He also had very good expertise in solubilization of drug molecules using cosolvency models. His research interest lies in the general area of Pharmaceutics and more recently in the development of nanoemulsions and self-nanoemulsifying formulations for therapeutic applications. He is author of over 180 journal articles and book chapter.
M. Skwarczynski The University of Queensland St Lucia, QLD (Australia)
Dr M. Skwarczynski received a Master degree in biotechnology and a PhD in chemistry from Wroclaw University of Technology (Poland). In 2004 he was awarded Japan Society for the Promotion of Science Postdoctoral Fellowship, and a grant to conduct research on paclitaxel.His research interest lies in the general area of medicinal chemistry and more recently in the development of nanomaterials for biomedical applications, vaccine delivery strategies, including design, chemoselective synthesis, conformational studies, and immunological properties of lipopeptide and polymer assembled multivalent vaccine candidates. He is author of over 70 journal articles and book chapters.
Xing-Jie Liang CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology of China Beijing (P.R.China)
Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing. Dr. Liang also holds a postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Currently Dr. Liang is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He has published more than 80 scientific publications..